Acute myeloid leukemia with the t(8;21) translocation: Clinical consequences and biological implications

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Bruserud, Oøystein ^a,b   Reikvam, Hakon ^a   Hatfield, Kimberley Joanne ^b   Kittang, Astrid Olsnes ^a,b   Hovland, Randi ^b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CALPAIN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; CONNEXIN 43; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYTARABINE; DNA DIRECTED RNA POLYMERASE; DNA METHYLTRANSFERASE; ETO PROTEIN; FLT3 LIGAND; GFI1 PROTEIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; JANUS KINASE 2; MICRORNA; NOTCH RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN; PROTEIN P53; RAS PROTEIN; RETINOIC ACID; STEM CELL FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR PAX5; TRANSCRIPTION FACTOR POU4F1; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AMINO TERMINAL SEQUENCE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CHROMOSOME 9; CHROMOSOME DELETION; CHROMOSOME TRANSLOCATION; CYTOGENETICS; DNA DAMAGE; EPIGENETICS; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE EXPRESSION PROFILING; GENE FREQUENCY; GENE REARRANGEMENT; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GRANULOCYTIC SARCOMA; HUMAN; IMMUNOPHENOTYPING; INTRACELLULAR SIGNALING; LEUKEMIA; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; MASTOCYTOSIS; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; MUTATION RATE; MYELOMASTOCYTIC LEUKEMIA; MYELOMASTOCYTOSIS; OVERALL SURVIVAL; PROGNOSIS; PROTEIN BINDING; PROTEIN DOMAIN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA SPLICING; TRISOMY 8; ARTICLE; GENE TRANSLOCATION; GENETICS; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; POLYMORPHISM, SINGLE NUCLEOTIDE; PREVALENCE; TRANSLOCATION, GENETIC;

EID: 79959366179     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/104631     Document Type: Review

References (211)

1. WHO, World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues 2008 4th Lyon, France International Agency for Cancer
2. Rowley J. D., Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia Annales de Genetique 1973 16 2 109 112
3. Arber D. A., Stein A. S., Carter N. H., Ikle D., Forman S. J., Slovak M. L., Prognostic impact of acute myeloid leukemia classification: importance of detection of recurring cytogenetic abnormalities and multilineage dysplasia on survival American Journal of Clinical Pathology 2003 119 5 672 680 (Pubitemid 37046388)
4. Valk P. J. M., Verhaak R. G. W., Beijen M. A., Erpelinck C. A. J., Van Waalwijk Van Doorn-Khosrovani S. B., Boer J. M., Beverloo H. B., Moorhouse M. J., Van Der Spek P. J., Lwenberg B., Delwel R., Prognostically useful gene-expression profiles in acute myeloid leukemia The New England Journal of Medicine 2004 350 16 1617 1628 (Pubitemid 38528701)
5. Cheng Y., Wang Y., Wang H., Chen Z., Lou J., Xu H., Wang H., Qian W., Meng H., Lin M., Jin J., Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China Leukemia 2009 23 10 1801 1806
6. Sanderson R. N., Johnson P. R. E., Moorman A. V., Roman E., Willett E., Taylor P. R., Proctor S. J., Bown N., Ogston S., Bowen D. T., Population-based demographic study of karyotypes in 1709 patients with adult acute myeloid leukemia Leukemia 2006 20 3 444 450 (Pubitemid 43291742)
7. Grimwade D., Hills R. K., Moorman A. V., Walker H., Chatters S., Goldstone A. H., Wheatley K., Harrison C. J., Burnett A. K., Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials Blood 2010 116 3 354 365
8. Klaus M., Haferlach T., Schnittger S., Kern W., Hiddemann W., Schoch C., Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization Cancer Genetics and Cytogenetics 2004 155 1 47 56 (Pubitemid 39446612)
9. Bacher U., Kern W., Schnittger S., Hiddemann W., Haferlach T., Schoch C., Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia Haematologica 2005 90 11 1502 1510 (Pubitemid 41658763)
10. Bruserud., Hovland R., Wergeland L., Huang T. S., Gjertsen B. T., Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of the effects of Flt3-ligand in AML cell populations with and without genetic Flt3 abnormalities Haematologica 2003 88 4 416 428 (Pubitemid 36547128)
11. Mrzek K., Marcucci G., Paschka P., Bloomfield C. D., Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia Current Opinion in Oncology 2008 20 6 711 718
12. Rubnitz J. E., Raimondi S. C., Halbert A. R., Tong X., Srivastava D. K., Razzouk B. I., Pui C. H., Downing J. R., Ribeiro R. C., Behm F. G., Characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience Leukemia 2002 16 10 2072 2077 (Pubitemid 35203450)
13. Raimondi S. C., Chang M. N., Ravindranath Y., Behm F. G., Gresik M. V., Steuber C. P., Weinstein H. J., Carrol A. J., Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a Cooperative Pediatric Oncology Group study-POG 8821 Blood 1999 94 11 3707 3716
14. Pession A., Rondelli R., Basso G., Rizzari C., Testi A. M., Fagioli F., De Stefano P., Locatelli F., Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols Leukemia 2005 19 12 2043 2053 (Pubitemid 41741596)
15. Perel Y., Auvrignon A., Leblanc T., Michel G., Reguerre Y., Vannier J.-P., Dalle J.-H., Gandemer V., Schmitt C., Mchinaud F., Lejars O., Piguet C., Couillaud G., Pautard B., Landman-Parker J., Thuret I., Aladjidi N., Baruchel A., Leverger G., Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefitmulticenter studies of the French LAME (Leucmie Aigu Myloblastique Enfant) Cooperative Group Leukemia 2005 19 12 2082 2089 (Pubitemid 41741600)
16. Wiemels J. L., Xiao Z., Buffler P. A., Maia A. T., Ma X., Dicks B. M., Smith M. T., Zhang L., Feusner J., Wiencke J., Pritchard-Jones K., Kempski H., Greaves M., In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia Blood 2002 99 10 3801 3805 (Pubitemid 34534554)
17. LaFiura K. M., Bielawski D. M., Posecion N. C., Ostrea E. M., Matherly L. H., Taub J. W., Ge Y., Association between prenatal pesticide exposures and the generation of leukemia-associated t(8;21) Pediatric Blood and Cancer 2007 49 5 624 628 (Pubitemid 350194424)
18. Manvelyan M., Kempf P., Weise A., Mrasek K., Heller A., Lier A., Hffken K., Fricke H. J., Sayer H. G., Liehr T., Mkrtcyhan H., Preferred co-localization of chromosome 8 and 21 in myeloid bone marrow cells detected by three dimensional molecular cytogenetics International Journal of Molecular Medicine 2009 24 3 335 341
19. Stuardo M., Martinez M., Hidalgo K., Montecino M., Javed A., Lian J. B., Stein G. S., Stein J. L., Gutirrez S. E., Altered chromatin modifications in AML1/RUNX1 breakpoint regions involved in (8;21) translocation Journal of Cellular Physiology 2009 218 2 343 349
20. Liddiard K., Hills R., Burnett A. K., Darley R. L., Tonks A., OGG1 is a novel prognostic indicator in acute myeloid leukaemia Oncogene 2010 29 13 2005 2012
21. Vieira L., Oliveira V., Ambrsio A. P., Marques B., Pereira A. M., Hagemeijer A., Boavida M. G., Translocation (8;17;15;21)(q22;q23;q15;q22) in acute myeloid leukemia (M2): a four-way variant of t(8;21) Cancer Genetics and Cytogenetics 2001 128 2 104 107 (Pubitemid 32706581)
22. Anelli L., Albano F., Zagaria A., Liso A., Cuneo A., Mancini M., Liso V., Rocchi M., Specchia G., Pericentric chromosome 8 inversion associated with the 5′ RUNX1/ 3′ CBFA2T1 gene in acute myeloid leukemia cases Annals of Hematology 2005 84 4 245 249 (Pubitemid 40425071)
23. Specchia G., Albano F., Anelli L., Zagaria A., Liso A., La Starza R., Mancini M., Sebastio L., Giugliano E., Saglio G., Liso V., Rocchi M., Insertions generating the 5′ RUNX1/ 3′ C8FA2T1 gene in acute myeloid leukemia cases show variable breakpoints Genes Chromosomes and Cancer 2004 41 1 86 91 (Pubitemid 38988741)
24. Peterson L. F., Boyapati A., Ahn E. Y., Biggs J. R., Akiko J. O., Lo M. C., Yan M., Zhang D. E., Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts Blood 2007 110 3 799 805 (Pubitemid 47267414)
25. Kuchenbauer F., Schnittger S., Look T., Gilliland G., Tenen D., Haferlach T., Hiddemann W., Buske C., Schoch C., Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO British Journal of Haematology 2006 134 6 616 619 (Pubitemid 44253604)
26. Peniket A. J., Wainscoat J., Side L., Del(9q) AML: clinical and cytological characteristics and prognostic implications British Journal of Haematology 2005 129 2 210 220 (Pubitemid 40562442)
27. Prbet T., Boissel N., Reutenauer S., Thomas X., Delaunay J., Cahn J. Y., Pigneux A., Quesnel B., Witz F., Thpot S., Ugo V., Terre C., Recher C., Tavernier E., Hunault M., Esterni B., Castaigne S., Guilhot F., Dombret H., Vey N., Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup Journal of Clinical Oncology 2009 27 28 4747 4753
28. Appelbaum F. R., Kopecky K. J., Tallman M. S., Slovak M. L., Gundacker H. M., Kim H. T., Dewald G. W., Kantarjian H. M., Pierce S. R., Estey E. H., The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations British Journal of Haematology 2006 135 2 165 173 (Pubitemid 44401613)
29. Narimatsu H., Iino M., Ichihashi T., Yokozawa T., Hayakawa M., Kiyoi H., Takeo T., Sawamoto A., Iida H., Tsuzuki M., Yanada M., Naoe T., Suzuki R., Sugiura I., Clinical significance of minimal residual disease in patients with t(8;21) acute myeloid leukemia in Japan International Journal of Hematology 2008 88 2 154 158
30. Wang Y. Y., Zhou G. B., Yin T., Chen B., Shi J. Y., Liang W. X., Jin X. L., You J. H., Yang G., Shen Z. X., Chen J., Xiong S. M., Chen G. Q., Xu F., Liu YI. W., Chen Z., Chen S. J., AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec Proceedings of the National Academy of Sciences of the United States of America 2005 102 4 1104 1109 (Pubitemid 40170733)
31. Paschka P., Marcucci G., Ruppert A. S., Mrzek K., Chen H., Kittles R. A., Vukosavljevic T., Perrotti D., Vardiman J. W., Carroll A. J., Kolitz J. E., Larson R. A., Bloomfield C. D., Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study Journal of Clinical Oncology 2006 24 24 3904 3911 (Pubitemid 46630738)
32. Shimada A., Taki T., Tabuchi K., KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group Blood 2006 107 5 1806 1809 (Pubitemid 43289357)
33. Boissel N., Leroy H., Brethon B., Philippe N., de Botton S., Auvrignon A., Raffoux E., Leblanc T., Thomas X., Hermine O., Quesnel B., Baruchel A., Leverger G., Dombret H., Preudhomme C., Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML) Leukemia 2006 20 6 965 970 (Pubitemid 43797286)
34. Cairoli R., Beghini A., Grillo G., Nadali G., Elice F., Ripamonti C. B., Colapietro P., Nichelatti M., Pezzetti L., Lunghi M., Cuneo A., Viola A., Ferrara F., Lazzarino M., Rodeghiero F., Pizzolo G., Larizza L., Morra E., Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study Blood 2006 107 9 3463 3468
35. Paschka P., Du J., Schlenk R. F., Mutations in the Fms-related tyrosine kinase 3 (FLT3) gene independently predict poor outcome in acute myeloid leukemia (AML) with t(8;21): a study of the outcome in acute myeloid leukemia (AML) with t(8;21): a study of the German-Austrian AML Study Group (AMLSG) ASH Annual Meeting Abstracts 2009 114 22. abstract no 825
36. Schnittger S., Bacher U., Kern W., Haferlach T., Haferlach C., JAK2V617F as progression marker in CMPD and as cooperative mutation in AML with trisomy 8 and t(8;21): a comparative study on 1103 CMPD and 269 AML cases Leukemia 2007 21 8 1843 1845 (Pubitemid 47090133)
37. Sritana N., Auewarakul C. U., KIT and FLT3 receptor tyrosine kinase mutations in acute myeloid leukemia with favorable cytogenetics: two novel mutations and selective occurrence in leukemia subtypes and age groups Experimental and Molecular Pathology 2008 85 3 227 231
38. Goemans B. F., Zwaan CH. M., Miller M., Zimmermann M., Harlow A., Meshinchi S., Loonen A. H., Hhlen K., Reinhardt D., Creutzig U., Kaspers G. J. L., Heinrich M. C., Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia Leukemia 2005 19 9 1536 1542 (Pubitemid 43090396)
39. Care R. S., Valk P. J. M., Goodeve A. C., Abu-Duhier F. M., Geertsma-Kleinekoort W. M. C., Wilson G. A., Gari M. A., Peake I. R., Lwenberg B., Reilly J. T., Incidence and prognosis of c-KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias British Journal of Haematology 2003 121 5 775 777 (Pubitemid 36718195)
40. Pollard J. A., Alonzo T. A., Gerbing R. B., Ho P. A., Zeng R., Ravindranath Y., Dahl G., Lacayo N. J., Becton D., Chang M., Weinstein H. J., Hirsch B., Raimondi S. C., Heerema N. A., Woods W. G., Lange B. J., Hurwitz C., Arceci R. J., Radich J. P., Bernstein I. D., Heinrich M. C., Meshinchi S., Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML Blood 2010 115 12 2372 2379
41. Schnittger S., Kohl T. M., Haferlach T., Kern W., Hiddemann W., Spiekermann K., Schoch C., KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival Blood 2006 107 5 1791 1799 (Pubitemid 43289355)
42. Dhner K., Du J., Corbacioglu A., Scholl C., Schlenk R. F., Dhner H., JAK2V617F mutations as cooperative genetic lesions in t(8;21)-positive acute myeloid leukemia Haematologica 2006 91 11 1569 1570 (Pubitemid 44736129)
43. Mrzek K., Bloomfield C. D., Clinical significance of the most common chromosome translocations in adult acute myeloid leukemia Journal of the National Cancer InstituteMonographs 2008 39 52 57
44. Urioste M., Martnez-Ramrez A., Cigudosa J. C., Mateo M. S., Martnez P., Contra T., Bentez J., Identification of ins(8;21) with AML1/ETO fusion in acute myelogenous leukemia M2 by molecular cytogenetics Cancer Genetics and Cytogenetics 2002 133 1 83 86 (Pubitemid 34224881)
45. Sweetser D. A., Peniket A. J., Haaland C., Blomberg A. A., Zhang Y., Zaidi S. T., Dayyani F., Zhao Z., Heerema N. A., Boultwood J., Dewald G. W., Paietta E., Slovak M. L., Willman C. L., Wainscoat J. S., Bernstein I. D., Daly S. B., Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia Genes Chromosomes and Cancer 2005 44 3 279 291 (Pubitemid 41397097)
46. Xiao Z., Liu S., Liu X., Yu M., Hao Y., Tetraploidy or near-tetraploidy clones with double 8;21 translocation: a non-random additional anomaly of acute myeloid leukemia with t(8;21)(q22;q22) Haematologica 2005 90 3 413 414 (Pubitemid 40388998)
47. Shih L. Y., Liang D. C., Huang C. F., Chang Y. T., Lai C. L., Lin T. H., Yang C. P., Hung I. J., Liu H. C., Jaing T. H., Wang L. Y., Yeh T. C., Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples Leukemia 2008 22 2 303 307
48. Coppersmith H. J., Kimand H.-G., Klug C., Differential contributions of c-kit activating mutations to promotion of AML1-ETO associated neoplasia ASH Annual Meeting Abstracts 2010 116 21. abstract no. 4195
49. Schessl C., Rawat V. P. S., Cusan M., Deshpande A., Kohl T. M., Rosten P. M., Spiekermann K., Humphries R. K., Schnittger S., Kern W., Hiddemann W., Quintanilla-Martinez L., Bohlander S. K., Feuring-Buske M., Buske C., The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice Journal of Clinical Investigation 2005 115 8 2159 2168 (Pubitemid 41134157)
50. Chou F.-S., Wunderlich M., Griesinger A., Mulloy J. C., N-RasG12D induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene Blood 2011 117 7 2237 2240
51. Hiwatari M., Taki T., Tsuchida M., Hanada R., Hongo T., Sako M., Hayashi Y., Novel missense mutations in the tyrosine kinase domain of the platelet-derived growth factor receptor (PDGFRA) gene in childhood acute myeloid leukemia with t(8;21) (q22;q22) or inv(16) (p13q22) [10] Leukemia 2005 19 3 476 477 (Pubitemid 40403334)
52. Leroy H., Roumier C., Huyghe P., Biggio V., Fenaux P., Preudhomme C., CEBPA point mutations in hematological malignancies Leukemia 2005 19 3 329 334 (Pubitemid 40409478)
53. Paschka P., Schlenk R. F., Gaidzik V. I., Habdank M., Krnke J., Bullinger L., Spth D., Kayser S., Zucknick M., Gtze K., Horst H.-A., Germing U., Dhner H., Dhner K., IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication Journal of Clinical Oncology 2010 28 22 3636 3643
54. Ley T. J., Ding L., Walter M. J., McLellan M. D., Lamprecht T., Larson D. E., Kandoth C., Payton J. E., Baty J., Welch J., Harris C. C., Lichti C. F., Townsend R. R., Fulton R. S., Dooling D. J., Koboldt D. C., Schmidt H., Zhang Q., Osborne J. R., Lin L., O'Laughlin M., McMichael J. F., Delehaunty K. D., McGrath S. D., Fulton L. A., Magrini V. J., Vickery T. L., Hundal J., Cook L. L., Conyers J. J., Swift G. W., Reed J. P., Alldredge P. A., Wylie T., Walker J., Kalicki J., Watson M. A., Heath S., Shannon W. D., Varghese N., Nagarajan R., Westervelt P., Tomasson M. H., Link D. C., Graubert T. A., DiPersio J. F., Mardis E. R., Wilson R. K., DNMT3A mutations in acute myeloid leukemia New England Journal of Medicine 2010 363 25 2424 2433
55. Gustafson S. A., Lin P., Chen S. U. S., Chen L., Abruzzo L. V., Luthra R., Medeiros L. J., Wang SA. A., Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome American Journal of Clinical Pathology 2009 131 5 647 655
56. Chang H., Chuang C. L., Hsien K. C., Therapy-related acute myeloid leukemia after concurrent chemoradiotherapy for esophageal cancer: report of two cases Tumori 2009 95 3 371 373
57. Owatari S., Otsuka M., Uozumi K., Takeshita T., Hanada S., Two cases of secondary acute myeloid leukemia accompanying adult T-cell leukemia/lymphoma International Journal of Hematology 2007 85 1 32 35 (Pubitemid 46193287)
58. Erickson P., Gao J., Chang K. S., Look T., Whisenant E., Raimondi S., Lasher R., Trujillo J., Rowley J., Drabkin H., Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt Blood 1992 80 7 1825 1831
59. Dowdy C. R., Xie R., Frederick D., Hussain S., Zaidi S. K., Vrad D. II, Javed A., Li X., Jones S. N., Lian J. B., van Wijnen A. J., Stein J. L., Stein G. S., Definitive hematopoiesis requires Runx1 C-terminal-mediated subnuclear targeting and transactivation Human Molecular Genetics 2009 19 6 1048 1057
60. Plevin M. J., Zhang J., Guo C., Roeder R. G., Ikura M., The acute myeloid leukemia fusion protein AML1-ETO targets E proteins via a paired amphipathic helix-like TBP-associated factor homology domain Proceedings of the National Academy of Sciences of the United States of America 2006 103 27 10242 10247 (Pubitemid 44051151)
61. Hug B. A., Lazar M. A., ETO interacting proteins Oncogene 2004 23 24 4270 4274 (Pubitemid 38758594)
62. Zaidi S. K., Dowdy C. R., Van Wijnen A. J., Lian J. B., Raza A., Stein J. L., Croce C. M., Stein G. S., Altered Runx1 subnuclear targeting enhances myeloid cell proliferation and blocks differentiation by activating a miR-24/MKP-7/MAPK network Cancer Research 2009 69 21 8249 8255
63. Wildonger J., Mann R. S., The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor Development 2005 132 10 2263 2272 (Pubitemid 40872797)
64. Qiu J., Wong J., Tweardy D. J., Dong S., Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor Oncogene 2006 25 28 3982 3993 (Pubitemid 43990754)
65. Lafiura K. M., Edwards H., Taub J. W., Matherly L. H., Fontana J. A., Mohamed A. N., Ravindranath Y., Ge Y., Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group Oncogene 2008 27 36 4933 4942
66. Yan M., Kanbe E., Peterson L. F., Boyapati A., Miao Y., Wang Y., Chen I. M., Chen Z., Rowley J. D., Willman C. L., Zhang D. E., A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis Nature Medicine 2006 12 8 945 949 (Pubitemid 44175147)
67. Yan M., Ahn E. Y., Hiebert S. W., Zhang D. E., RUNX1/AML1 DNA-binding domain and ETO/MTG8 NHR2-dimerization domain are critical to AML1-ETO9a leukemogenesis Blood 2009 113 4 883 886
68. Tsoulaki O., Lacaudand G., Kouskoff V., Characterisation of AML1-ETO9A leukaemiogenesis using an inducible murine model Haematologica 2010 95 s2. abstract no 0025
69. Kozu T., Fukuyama T., Yamami T., Akagi K., Kaneko Y., MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21) Genes Chromosomes and Cancer 2005 43 1 45 53 (Pubitemid 40490354)
70. Mannari D., Gascoyne D., Dunne J., Chaplin T., Young B., A novel exon in AML1-ETO negatively influences the clonogenic potential of the t(8;21) in acute myeloid leukemia Leukemia 2010 24 4 891 894
71. Khandanpour C., Thiede C., Valk P. J. M., Sharif-Askari E., Nckel H., Lohmann D., Horsthemke B., Siffert W., Neubauer A., Grzeschik K. H., Bloomfield C. D., Marcucci G., Maharry K., Slovak M. L., Van Der Reijden B. A., Jansen J. H., Schackert H. K., Afshar K., Schnittger S., Peeters J. K., Kroschinsky F., Ehninger G., Lowenberg B., Dhrsen U., Mry T., Avariant allele of growth factor independence 1 (GFI1) is associated with acute myeloid leukemia Blood 2010 115 12 2462 2472
72. Roudaia L., Cheney M. D., Manuylova E., Chen W., Morrow M., Park S., Lee C. T., Kaur P., Williams O., Bushweller J. H., Speck N. A., CBF is critical for AML1-ETO and TEL-AML1 activity Blood 2009 113 13 3070 3079
73. Liu S., Klisovic R. B., Vukosavljevic T., Yu J., Paschka P., Huynh L., Pang J., Neviani P., Liu Z., Blum W., Chan K. K., Perrotti D., Marcucci G., Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells Journal of Pharmacology and Experimental Therapeutics 2007 321 3 953 960 (Pubitemid 46762689)
74. Bakshi R., Zaidi S. K., Pande S., Hassan M. Q., Young D. W., Montecino M., Lian J. B., van Wijnen A. J., Stein J. L., Stein G. S., The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes Journal of Cell Science 2008 121 23 3981 3990
75. Ahn E. Y., Yan M., Malakhova O. A., Lo M. C., Boyapati A., Ommen H. B., Hines R., Hokland P., Zhang D. E., Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis Proceedings of the National Academy of Sciences of the United States of America 2008 105 44 17103 17108
76. Liu S., Shen T., Huynh L., Klisovic M. I., Rush L. J., Ford J. L., Yu J., Becknell B., Li YU., Liu C., Vukosavljevic T., Whitman S. P., Chang K. S., Byrd J. C., Perrotti D., Plass C., Marcucci G., Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia Cancer Research 2005 65 4 1277 1284 (Pubitemid 40270154)
77. Osman D., Gobert V., Ponthan F., Heidenreich O., Haenlin M., Waltzer L., A Drosophila model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO Proceedings of the National Academy of Sciences of the United States of America 2009 106 29 12043 12048
78. Corpora T., Roudaia L., Oo M., Structure of the AML1-ETO NHR3-PKA(RIIalpha) complex and its contribution to AML1-ETO activity Journal of Molecular Biology 2010 402 3 560 577
79. Park S., Chen W., Cierpicki T., Tonelli M., Cai X., Speck N. A., Bushweller J. H., Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity Blood 2009 113 15 3558 3567
80. Ibaez V., Sharma A., Buonamici S., Verma A., Kalakonda S., Wang J., Kadkol S., Saunthararajah Y., AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation Cancer Research 2004 64 13 4547 4554 (Pubitemid 38856927)
81. Wichmann C., Chen L., Heinrich M., Baus D., Pfitzner E., Zrnig M., Ottmann O. G., Grez M., Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells Cancer Research 2007 67 5 2280 2289 (Pubitemid 46424248)
82. Vangala R. K., Heiss-Neumann M. S., Rangatia J. S., Singh S. M., Schoch C., Tenen D. G., Hiddemann W., Behre G., The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia Blood 2003 101 1 270 277 (Pubitemid 36025918)
83. Fuchs O., Provaznikova D., Kocova M., Kostecka A., Cvekova P., Neuwirtova R., Kobylka P., Cermak J., Brezinova J., Schwarz J., Markova J., Salaj P., Klamova H., Maaloufova J., Lemez P., Novakova L., Benesova K., CEBPA polymorphisms and mutations in patients with acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma and non-Hodgkin's lymphoma Blood Cells, Molecules, and Diseases 2008 40 3 401 405
84. Westendorf J. J., Yamamoto C. M., Lenny N., Downing J. R., Selsted M. E., Hiebert S. W., The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-, inhibits C/EBP- -dependent transcription, and blocks granulocytic differentiation Molecular and Cellular Biology 1998 18 1 322 333 (Pubitemid 28021043)
85. Rochford J. J., Semple R. K., Laudes M., Boyle K. B., Christodoulides C., Mulligan C., Lelliott C. J., Schinner S., Hadaschik D., Mahadevan M., Sethi J. K., Vidal-Puig A., O'Rahilly S., ETO/MTG8 is an inhibitor of C/EBP activity and a regulator of early adipogenesis Molecular and Cellular Biology 2004 24 22 9863 9872 (Pubitemid 39458813)
86. Fortier J. M., Payton J. E., Cahan P., Ley T. J., Walter M. J., Graubert T. A., POU4F1 is associated with t(8;21) acute myeloid leukemia and contributes directly to its unique transcriptional signature Leukemia 2010 24 5 950 957
87. Tiacci E., Pileri S., Orleth A., Pacini R., Tabarrini A., Frenguelli F., Liso A., Diverio D., Lo-Coco F., Falini B., PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)-acute myelogenous leukemia Cancer Research 2004 64 20 7399 7404 (Pubitemid 39372080)
88. Valbuena J. R., Medeiros L. J., Rassidakis G. Z., Hao S., Wu C. D., Chen L., Lin P., Expression of B cell-specific activator protein/PAX5 in acute myeloid leukemia with t(8;21)(q22;q22) American Journal of Clinical Pathology 2006 126 2 235 240 (Pubitemid 44162570)
89. Fazi F., Racanicchi S., Zardo G., Starnes L. M., Mancini M., Travaglini L., Diverio D., Ammatuna E., Cimino G., Lo-Coco F., Grignani F., Nervi C., Epigenetic silencing of the myelopoiesis regulator microRNA-223 by the AML1/ETO oncoprotein Cancer Cell 2007 12 5 457 466 (Pubitemid 350046404)
90. Xu M., Li D., Lu Y., Chen G. Q., Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene Experimental Hematology 2007 35 8 1249 1255 (Pubitemid 47096757)
91. Krejci O., Wunderlich M., Geiger H., Chou FU. S., Schleimer D., Jansen M., Andreassen P. R., Mulloy J. C., P53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death Blood 2008 111 4 2190 2199 (Pubitemid 351451533)
92. Rhoades K. L., Hetherington C. J., Rowley J. D., Hiebert S. W., Nucifora G., Tenen D. G., Zhang D. E., Synergistic up-regulation of the myeloid-specific promoter for the macrophage colony-stimulating factor receptor by AML1 and the t(8;21) fusion protein may contribute to leukemogenesis Proceedings of the National Academy of Sciences of the United States of America 1996 93 21 11895 11900 (Pubitemid 26347220)
93. Shimizu K., Kitabayashi I., Kamada N., Abe T., Maseki N., Suzukawa K., Ohki M., AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon Blood 2000 96 1 288 296 (Pubitemid 30456484)
94. Klampfer L., Zhang J., Zelenetz A. O., Uchida H., Nimer S. D., The AML1/ETO fusion protein activates transcription of BCL-2 Proceedings of the National Academy of Sciences of the United States of America 1996 93 24 14059 14064 (Pubitemid 26424245)
95. Yang G., Khalaf W., Van De Locht L., Jansen J. H., Gao M., Thompson M. A., Van Der Reijden B. A., Gutmann D. H., Delwel R., Clapp D. W., Hiebert S. W., Transcriptional repression of the neurofibromatosis-1 tumor suppressor by the t(8;21) fusion protein Molecular and Cellular Biology 2005 25 14 5869 5879 (Pubitemid 40946544)
96. Mulloy J. C., Jankovic V., Wunderlich M., Delwel R., Cammenga J., Krejci O., Zhao H., Valk P. J. M., Lowenberg B., Nimer S. D., AML1-ETO fusion protein up-regulates TRKA mRNA expression in human CD34+ cells, allowing nerve growth factor-induced expansion Proceedings of the National Academy of Sciences of the United States of America 2005 102 11 4016 4021 (Pubitemid 40392508)
97. Peterson L. F., Yan M., Zhang D. E., The p21 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO Blood 2007 109 10 4392 4398 (Pubitemid 46743408)
98. Li X. I., Xu Y. A. B., Wang Q., Lu Y., Zheng Y., Wang Y. C., Lbbert M., Zhao K. E. W., Chen G. Q., Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells Journal of Cellular Physiology 2006 208 3 594 601 (Pubitemid 44141884)
99. Guinn B. A., Mohamedali A., Mills K. I., Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia Biomark Insights 2007 2 69 79
100. Boyapati A., Yan M., Peterson L. F., Biggs J. R., Le Beau M. M., Zhang D. E., Aleukemia fusion protein attenuates the spindle checkpoint and promotes aneuploidy Blood 2007 109 9 3963 3971 (Pubitemid 46641749)
101. Tabe Y., Jin L., Contractor R., Gold D., Ruvolo P., Radke S., Xu Y., Tsutusmi-Ish Y. II, Miyake K., Miyake N., Kondo S., Ohsaka A., Nagaoka I., Andreeff M., Konopleva M., Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1 Cell Death and Differentiation 2007 14 8 1443 1456 (Pubitemid 47086732)
102. Gao F. H., Wang Q., Wu Y. L., Li XI., Zhao KE. W., Chen G. Q., c-Jun N-terminal kinase mediates AML1-ETO protein-induced connexin-43 expression Biochemical and Biophysical Research Communications 2007 356 2 505 511 (Pubitemid 46463947)
103. Erkeland S. J., Palande K. K., Valkhof M., Gits J., Oorschot A. D. V., Touw I. P., The gene encoding thioredoxin-interacting protein (TXNIP) is a frequent virus integration site in virus-induced mouse leukemia and is overexpressed in a subset of AML patients Leukemia Research 2009 33 10 1367 1371
104. Shikami M., Miwa H., Nish K. II, Kyo T., Tanaka I., Shiku H., Kita K., Nitta M., Low p53 expression of acute myelocytic leukemia cells with t(8;21) chromosome abnormality: association with low p14 expression Leukemia Research 2006 30 4 379 383 (Pubitemid 43254958)
105. Sinenko S. A., Hung T., Moroz T., Tran Q.-M., Sidhu S., Cheney M. D., Speck N. A., Banerjee U., Genetic manipulation of AML1-ETO-induced expansion of hematopoietic precursors in a Drosophila model Blood 2010 116 22 4612 4620
106. Foss B., Hervig T., Bruserud., Connexins are active participants of hematopoietic stem cell regulation Stem Cells and Development 2009 18 6 807 812
107. Foss B., Tronstad K. J., Bruserud., Connexin-based signaling in acute myelogenous leukemia (AML) Biochimica et Biophysica Acta 2010 1798 1 1 8
108. Okumura A. J., Peterson L. F., Okumura F., Boyapati A., Zhang D. E., T(8;21)(q22;q22) fusion proteins preferentially bind to duplicated AML1/RUNX1 DNA-binding sequences to differentially regulate gene expression Blood 2008 112 4 1392 1401
109. Rossetti S., Hoogeveen A. T., Liang P., Stanciu C., van der Spek P., Sacchi N., A distinct epigenetic signature at targets of a leukemia protein BMC Genomics 2007 8, article 38
110. Rodrigues P. C., Oliveira S. N., Viana M. B., Matsuda E. I., Nowill A. E., Brandalise S. R., Yunes J. A., Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia Pediatric Blood and Cancer 2007 49 2 133 138 (Pubitemid 47041101)
111. Balkhi M. Y., Trivedi A. K., Geletu M., Christopeit M., Bohlander S. K., Behre H. M., Behre G., Proteomics of acute myeloid leukaemia: cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications Oncogene 2006 25 53 7041 7058 (Pubitemid 44722072)
112. Hiramatsu A., Miwa H., Shikami M., Ikai T., Tajima E., Yamamoto H., Imai N., Hattori A., Kyo T., Watarai M., Miura K., Satoh A., Itoh M., Imamura A., Mihara H., Katoh Y., Nitta M., Disease-specific expression of VEGF and its receptors in AML cells: possible autocrine pathway of VEGF/type1 receptor of VEGF in t(15;17) AML and VEGF/type2 receptor of VEGF in t(8;21) AML Leukemia and Lymphoma 2006 47 1 89 95 (Pubitemid 43101730)
113. Dias S., Hattori K., Zhu Z., Heissig B., Choy M., Lane W., Wu Y., Chadburn A., Hyjek E., Gill M., Hicklin D. J., Witte L., Moore M. A. S., Raf S. II, Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration Journal of Clinical Investigation 2000 106 4 511 521 (Pubitemid 30666384)
114. Imai N., Miwa H., Shikami M., Suganuma K., Gotoh M., Hiramatsu A., Wakabayashi M., Watarai M., Hanamura I., Imamura A., Mihara H., Shitara K., Shibuya M., Nitta M., Growth inhibition of AML cells with specific chromosome abnormalities by monoclonal antibodies to receptors for vascular endothelial growth factor Leukemia Research 2009 33 12 1650 1657
115. Imai N., Shikami M., Miwa H., Suganuma K., Hiramatsu A., Watarai M., Satoh A., Itoh M., Imamura A., Mihara H., Nitta M., t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt British Journal of Haematology 2006 135 5 673 682 (Pubitemid 44674078)
116. Alcalay M., Meani N., Gelmetti V., Fantozzi A., Fagioli M., Orleth A., Riganelli D., Sebastiani C., Cappelli E., Casciari C., Sciurpi M. T., Mariano A. R., Minardi S. P., Luzi L., Muller H., Di Fiore P. P., Frosina G., Pelicci P. G., Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair Journal of Clinical Investigation 2003 112 11 1751 1761 (Pubitemid 38063733)
117. Ersvaer E., Hatfield K., Reikvam H., Bruserud O., Future perspectives: therapeutic targeting of NOTCH signalling may become a strategy in patients receiving stem cell transplantation for hematologic malignancies Bone Marrow Research 2011 2011
118. Martinez N., Drescher B., Riehle H., Cullman C., Vornlocher H. P., Ganser A., Heil G., Nordheim A., Krauter J., Heidenreich O., The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells BMC Cancer 2004 4, article 44
119. Ichikawa H., Tanabe K., Mizushima H., Hayashi Y., Mizutani S., Ish E. II, Hongo T., Kikuchi A., Satake M., Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia British Journal of Haematology 2006 135 3 336 347 (Pubitemid 44484839)
120. Dhner H., Estey E. H., Amadori S., Appelbaum F. R., Bchner T., Burnett A. K., Dombret H., Fenaux P., Grimwade D., Larson R. A., Lo-Coco F., Naoe T., Niederwieser D., Ossenkoppele G. J., Sanz M. A., Sierra J., Tallman M. S., Lwenberg B., Bloomfield C. D., Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet Blood 2010 115 3 453 474
121. Rowe D., Cotterill S. J., Ross F. M., Bunyan D. J., Vickers S. J., Bryon J., McMullan D. J., Griffiths M. J., Reilly J. T., Vandenberghe E. A., Wilson G., Watmore A. E., Bown N. P., Cytogenetically cryptic AML1ETO and CBF MYH11 gene rearrangements: incidence in 412 cases of acute myeloid leukaemia British Journal of Haematology 2000 111 4 1051 1056 (Pubitemid 32104915)
122. Sarriera J. E., Albitar M., Estrov Z., Gidel C., Aboul-Na R. Sr., Manshouri T., Kornblau S., Chang K. S., Kantarjian H., Estey E., Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing Leukemia 2001 15 1 57 61 (Pubitemid 32124069)
123. Weerkamp F., Dekking E., Ng Y. Y., van der Velden V. H. J., Wai H., Bttcher S., Brggemann M., van der Sluijs A. J., Koning A., Boeckx N., Van Poecke N., Lucio P., Mendona A., Sedek L., Szczepaski T., Kalina T., Kovac M., Hoogeveen P. G., Flores-Montero J., Orfao A., Macintyre E., Lhermitte L., Chen R., Brouwer-De Cock K. A. J., van der Linden A., Noordijk A. L., Comans-Bitter W. M., Staal F. J. T., van Dongen J. J. M., Flow cytometric immunobead assay for the detection of BCR-ABL fusion proteins in leukemia patients Leukemia 2009 23 6 1106 1117
124. De Braekeleer E., Douet-Guilbert N., Morel F., Le Bris M.-J., Frec C., De Braekeleer M., RUNX1 translocations and fusion genes in malignant hemopathies Future Oncology 2011 7 1 77 91
125. Gjertsen B. T., yan A. M., Marzolf B., Hovland R., Gausdal G., Dskeland S. O., Dimitrov K., Golden A., Kalland K. H., Hood L., Bruserud., Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses Journal of Hematotherapy and Stem Cell Research 2002 11 3 469 481 (Pubitemid 34615032)
126. Bruserud., Tjnnfjord G., Gjertsen B. T., Foss B., Ernst P., New strategies in the treatment of acute myelogenous leukemia: mobilization and transplantation of autologous peripheral blood stem cells in adult patients Stem Cells 2000 18 5 343 351
127. Rowe D., Bown N. P., Albitar M., Estey E., Diagnostic detection of AML1/ETO gene fusion by polymerase chain reaction Leukemia 2002 16 8 1576 1577
128. Van Dongen J. J.M., Macintyre E. A., Gabert J. A., Delabesse E., Rossi V., Saglio G., Gottardi E., Rambaldi A., Dotti G., Griesinger F., Parreira A., Gameiro P., Diz M. G., Malec M., Langerak A. W., San Miguel J. F., Biondi A., Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia Leukemia 1999 13 12 1901 1928
129. Gabert J., Beillard E., van der Velden V. H.J., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J. M., Cav H., Pane F., Aerts J. L.E., De Micheli D., Thirion X., Pradel V., Gonzlez M., Viehmann S., Malec M., Saglio G., van Dongen J. J.M., Standardization and quality control studies of 'real time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemiaa Europe Against Cancer Program Leukemia 2003 17 12 2318 2357 (Pubitemid 38072573)
130. Tobal K., Liu Yin J. A., Diagnosis and monitoring of AML1-MTG8 (ETO)-positive acute myeloid leukemia by qualitative and real-time quantitative RT-PCR Methods in molecular medicine. 2006 125 149 161
131. Ommen H. B., stergaard M., Yan M., Brndstrup K., Zhang D. E., Hokland P., Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse European Journal of Haematology 2010 84 2 128 132
132. Pallisgaard N., Hokland P., Riishj D. C., Pedersen B., Jrgensen P., Multiplex reverse transcription-polymerase chain reaction for simultaneous screening of 29 translocations and chromosomal aberrations in acute leukemia Blood 1998 92 2 574 588 (Pubitemid 28323721)
133. Lee D. A., Harris C. P., Gresik V. M., Rao P., Lau C. C., Granulocytic sarcoma presenting as pneumonia in a child with t(8;21) acute myelogenous leukemia: diagnosis by flourescent in situ hybridization Journal of Pediatric Hematology/Oncology 2004 26 7 431 434 (Pubitemid 39025255)
134. Arber D. A., Glackin C., Lowe G., Medeiros L. J., Slovak M. L., Presence of t(8;21)(q22;q22) in myeloperoxidase-positive, myeloid surface antigen-negative acute myeloid leukemia American Journal of Clinical Pathology 1997 107 1 68 73 (Pubitemid 27104639)
135. Zheng J., Wang X., Hu Y. U., Yang J., Liu J., He Y., Gong Q., Yao J., Li X., Du W., Huang S., A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China Cytometry Part BClinical Cytometry 2008 74 1 25 29
136. De J., Zanjani R., Hibbard M., Davis B. H., Immunophenotypic profile predictive off KIT activating mutations in AML1-ETO leukemia American Journal of Clinical Pathology 2007 128 4 550 557 (Pubitemid 47584431)
137. Pileri S. A., Ascani S., Cox M. C., Campidelli C., Bacci F., Piccioli M., Piccaluga P. P., Agostinelli C., Asioli S., Novero D., Bisceglia M., Ponzoni M., Gentile A., Rinaldi P., Franco V., Vincelli D., Pileri A., Gasbarra R., Falini B., Zinzani P. L., Baccarani M., Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients Leukemia 2007 21 2 340 350 (Pubitemid 46158129)
138. Neiman R. S., Barcos M., Berard C., Granulocytic sarcoma: a clinicopathologic study of 61 biopsied cases Cancer 1981 48 6 1426 1437 (Pubitemid 11042596)
139. Kottaridis P. D., Ketley N., Peggs K., Chakraverty R., Ralleigh G., Shaw P., Pezzella F., Goldstone A. H., Devereux S., Mackinnon S., An unusual case of intrapulmonary granulocytic sarcoma presenting as interstitial pneumonitis following allogeneic bone marrow transplantation for acute myeloid leukaemia and responding to donor lymphocyte infusion Bone Marrow Transplantation 1999 24 7 807 809 (Pubitemid 29469284)
140. Chevallier P., Mohty M., Lioure B., Michel G., Contentin N., Deconinck E., Bordigoni P., Vernant J. P., Hunault M., Vigouroux S., Blaise D., Tabrizi R., Buzyn A., Socie G., Michallet M., Volteau C., Harousseau J. L., Allogeneic hematopoietic stem-cell transplantation for myeloid sarcoma: a retrospective study from the SFGM-TC Journal of Clinical Oncology 2008 26 30 4940 4943
141. Tsimberidou A. M., Kantarjian H. M., Wen S., Keating M. J., O'Brien S., Brandt M., Pierce S., Freireich E. J., Medeiros L. J., Estey E., Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia Cancer 2008 113 6 1370 1378
142. Colovi N., Colovi M., Cemeriki V., Terzi T., Ivanovi S., Skender M., Boskovi D., Granulocytic sarcoma of the brain in a patient with acute myeloid leukemia Acta chirurgica Iugoslavica. 2004 51 3 129 131
143. Al-Sobbi E. M., Jeha T. M., Al-Taher M. I., Granulocytic sarcoma causing cord compression in a pregnant woman with acute myeloid leukemia and t(8;21) Saudi Medical Journal 2008 29 11 1658 1661
144. Tamaki H., Yoshihara S., Fujioka T., Kawakami M., Oka Y., Ogawa H., Molecular detection of AML1-MTG8-positive cells in peripheral blood from a patient with isolated extramedullary relapse of t(8;21) acute myeloid leukemia Leukemia 2009 23 2 424 426
145. Wong K. F., Siu L. L. P., Wong W. S., Aleukaemic acute myeloid leukaemia with t(8;21)(q22;q22): images in haematology British Journal of Haematology 2009 146 4 345
146. Jost E., Lorenzen J., Haage P., Bos G., Beelen D., Galm O., Gehbauer G., Osieka R., Heart and muscle involvement by extra-medullary myeloid leukemia: a case report and review of the literature Leukemia and Lymphoma 2005 46 12 1819 1824 (Pubitemid 43203119)
147. Felice M. S., Zubizarreta P. A., Alfaro E. M., Gallego M. S., Cygler A. M., Rosso D. A., Rossi J. G., Sackmann-Muriel F., Good outcome of children with acute myeloid leukemia and t(8;21)(q22;q22), even when associated with granulocytic sarcoma: a report from a single institution in Argentina Cancer 2000 88 8 1939 1944 (Pubitemid 30213005)
148. Pullarkat S. T., Pullarkat V., Kroft S. H., Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia Journal of Hematopathology 2009 2 1 27 33
149. Pullarkat V., Bedell V., Kim Y., Bhatia R., Nakamura R., Forman S., Sun J., Senitzer D., Slovak M. L., Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone Leukemia Research 2007 31 2 261 265 (Pubitemid 44854181)
150. Sperr W. R., Drach J., Hauswirth A. W., Ackermann J., Mitterbauer M., Mitterbauer G., Foedinger M., Fonatsch C., Simonitsch-Klupp I., Kalhs P., Valent P., Myelomastocytic leukemia: evidence for the origin of mast cells from the leukemic clone and eradication by allogeneic stem cell transplantation Clinical Cancer Research 2005 11 19 I 6787 6792 (Pubitemid 41428732)
151. Pullarkat S. T., Sedarat F., Paquette R., Said J., Systemic mastocytosis with plasma cell dyscrasia: report of a case Leukemia Research 2008 32 7 1160 1163 (Pubitemid 351514789)
152. Cairoli R., Ripamonti C. B., Beghini A., Granata S., Grillo G., Brioschi M., Nadali G., Viola A., Cattaneo C., Inropido L., Ravelli E., Bertani G., Pezzetti L., Nichelatti M., Marocchi A., Rossi G., Pizzolo G., Ferrara F., Nosari A. M., Morra E., Total serum tryptase: a predictive marker for KIT mutation in acute myeloid leukemia Leukemia Research 2009 33 9 1282 1284
153. McCormack E., Bruserud O., Gjertsen B. T., Review: genetic models of acute myeloid leukaemia Oncogene 2008 27 27 3765 3779 (Pubitemid 351862057)
154. Yuan Y., Zhou L., Miyamoto T., Iwasaki H., Harakawa N., Hetherington C. J., Burel S. A., Lagasse E., Weissman I. L., Akashi K., Zhang D. E., AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations Proceedings of the National Academy of Sciences of the United States of America 2001 98 18 10398 10403 (Pubitemid 32803031)
155. Bullinger L., Dhner K., Bair E., Frhling S., Schlenk R. F., Tibshirani R., Dhner H., Pollack J. R., Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia The New England Journal of Medicine 2004 350 16 1605 1616 (Pubitemid 38501163)
156. Miller B. G., Stamatoyannopoulos J. A., Integrative meta-analysis of differential gene expression in acute myeloid leukemia PLoS ONE 2010 5
157. Verhaak R. G. W., Wouters B. J., Erpelinck C. A. J., Abbas S., Beverloo H. B., Lugthart S., Lwenberg B., Delwel R., Valk P. J. M., Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling Haematologica 2009 94 1 131 134
158. Lck S. C., Russ A. C., Du J., Gaidzik V., Schlenk R. F., Pollack J. R., Dhner K., Dhner H., Bullinger L., KIT mutations confer a distinct gene expression signature in core binding factor leukaemia: research paper British Journal of Haematology 2010 148 6 925 937
159. Reikvam H., Olsnes A. M., Gjertsen B. T., Ersvar E., Bruserud O., Nuclear factor-B signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia Critical Reviews in Oncogenesis 2009 15 1-2 1 41
160. Bullinger L., Rcker F. G., Kurz S., Du J., Scholl C., Sander S., Corbacioglu A., Lottaz C., Krauter J., Frhling S., Ganser A., Schlenk R. F., Dhner K., Pollack J. R., Dhner H., Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia Blood 2007 110 4 1291 1300 (Pubitemid 47281428)
161. Reikvam H., Hatfield K., Ersvaer E., Ryningen A., Bruserud., Pharmacological targeting of the PI3K-AKT/PKB-mTOR pathway alters local angioregulation in acute myelogenous leukemia Haematologica 2010 95 s2. abstract no 0634
162. Doepfner K. T., Boller D., Arcaro A., Targeting receptor tyrosine kinase signaling in acute myeloid leukemia Critical Reviews in Oncology/Hematology 2007 63 3 215 230 (Pubitemid 47126864)
163. Paydas S., Tanriverdi K., Yavuz S., Disel U., Baslamisli F., Burgut R., PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects American Journal of Hematology 2005 79 4 257 261 (Pubitemid 41098836)
164. Liseth K., Ersvaer E., Hervig T., Bruserud., Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience Journal of Biomedicine and Biotechnology 2010 2010
165. Pang A., Au W. Y., Kwong Y. L., Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow Leukemia Research 2004 28 9 973 977 (Pubitemid 38953652)
166. Stoeckle C., Gouttefangeas C., Hammer M., Weber E., Melms A., Tolosa E., Cathepsin W expressed exclusively in CD8+ T cells and NK cells, is secreted during target cell killing but is not essential for cytotoxicity in human CTLs Experimental Hematology 2009 37 2 266 275
167. Park T., Zong Ping Chen., Leavitt J., Activation of the leukocyte plastin gene occurs in most human cancer cells Cancer Research 1994 54 7 1775 1781 (Pubitemid 24116185)
168. Silacci P., Mazzolai L., Gauci C., Stergiopulos N., Yin H. L., Hayoz D., Gelsolin superfamily proteins: key regulators of cellular functions Cellular and Molecular Life Sciences 2004 61 19-20 2614 2623 (Pubitemid 39586521)
169. Neufeld G., Kessler O., The semaphorins: versatile regulators of tumour progression and tumour angiogenesis Nature Reviews Cancer 2008 8 8 632 645
170. Jongen-Lavrencic M., Sun S. U. M., Dijkstra M. K., Valk P. J. M., Lwenberg B., MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia Blood 2008 111 10 5078 5085
171. Li Z., Lu J., Sun M., Mi S., Zhang H., Luo R. T., Chen P., Wang Y., Yan M., Qian Z., Neilly M. B., Jin J., Zhang Y., Bohlander S. K., Zhang D. E., Larson R. A., Le Beau M. M., Thirman M. J., Golub T. R., Rowley J. D., Chen J., Distinct microRNA expression profiles in acute myeloid leukemia with common translocations Proceedings of the National Academy of Sciences of the United States of America 2008 105 40 15535 15540
172. Pedranzini L., Mottadelli F., Ronzoni S., Rossella F., Ferracin M., Magnani I., Roversi G., Colapietro P., Negrini M., Pelicci P. G., Larizza L., Differential cytogenomics and miRNA signature of the Acute Myeloid Leukaemia Kasumi-1 cell line CD34(+)38(-) compartment Leukemia Research 2010 34 10 1287 1295
173. Esteller M., Molecular origins of cancer: epigenetics in cancer The New England Journal of Medicine 2008 358 11 1148 1096
174. Bullinger L., Ehrich M., Dhner K., Schlenk R. F., Dhner H., Nelson M. R., Van Den Boom D., Quantitative DNA methylation predicts survival in adult acute myeloid leukemia Blood 2010 115 3 636 642
175. Figueroa M. E., Lugthart S., Li Y., Erpelinck-Verschueren C., Deng X., Christos P. J., Schifano E., Booth J., van Putten W., Skrabanek L., Campagne F., Mazumdar M., Greally J. M., Valk P. J. M., Lwenberg B., Delwel R., Melnick A., DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia Cancer Cell 2010 17 1 13 27
176. Alvarez S., Suela J., Valencia A., Fernndez A., Wunderlich M., Agirre X., Prsper F., Martn-Subero J. I., Maiques A., Acquadro F., Perales S. R., Calasanz M. J., Roman-Gmez J., Siebert R., Mulloy J. C., Cervera J., Sanz M. A., Esteller M., Cigudosa J. C., DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia PLoS ONE 2010 5 8
177. Mller-Tidow C., Klein H.-U., Hascher A., Isken F., Tickenbrock L., Thoennissen N., Agrawal-Singh S., Tschanter P., Disselhoff C., Wang Y., Becker A., Thiede C., Ehninger G., Zur Stadt U., Koschmieder S., Seidl M., Mller F. U., Schmitz W., Schlenke P., McClelland M., Berdel W. E., Dugas M., Serve H., Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia Blood 2010 116 18 3564 3571
178. Narimatsu H., Yokozawa T., Iida H., Tsuzuki M., Hayakawa M., Takeo T., Iino M., Ichihashi T., Kato C., Sawamoto A., Sao H., Yanada M., Emi N., Kiyoi H., Yamaguchi T., Naoe T., Suzuki R., Sugiura I., Clinical characteristics and outcomes in patients with t(8;21) acute myeloid leukemia in Japan Leukemia 2008 22 2 428 432 (Pubitemid 351250550)
179. Lin P., Chen L., Luthra R., Konoplev S. N., Wang X., Medeiros L. J., Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations Modern Pathology 2008 21 8 1029 1036
180. Nguyen S., Leblanc T., Fenaux P., Witz F., Blaise D., Pigneux A., Thomas X., Rigal-Huguet F., Lioure B., Auvrignon A., Fire D., Reiffers J., Castaigne S., Leverger G., Harousseau J. L., Soci G., Dombret H., A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML intergroup Blood 2002 99 10 3517 3523 (Pubitemid 34534517)
181. Cornelissen J. J., Van Putten W. L. J., Verdonck L. F., Theobald M., Jacky E., Daenen S. M. G., Van Marwijk Kooy M., Wijermans P., Schouten H., Huijgens P. C., Van Der Lelie H., Fey M., Ferrant A., Maertens J., Gratwohl A., Lowenberg B., Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007 109 9 3658 3666 (Pubitemid 46641712)
182. Shin H.-J., Chung J., Kim H. J., Bone marrow cellularity is a single most important independent prognostic factor in AML patients with t(8;21) ASH Annual Meeting Abstracts 2010 116 21. abstract no 1707
183. Harrison C. J., Hills R. K., Moorman A. V., Grimwade D. J., Hann I., Webb D. K.H., Wheatley K., De Graaf S. S.N., Van Den Berg E., Burnett A. K., Gibson B. E.S., Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12 Journal of Clinical Oncology 2010 28 16 2674 2681
184. Von Neuhoff C., Reinhardt D., Sander A., Zimmermann M., Bradtke J., Betts D. R., Zemanova Z., Stary J., Bourquin J.-P., Haas O. A., Dworzak M. N., Creutzig U., Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98 Journal of Clinical Oncology 2010 28 16 2682 2689
185. Smith F. O., Alonzo T. A., Gerbing R. B., Woods W. G., Arceci R. J., Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891 Leukemia 2005 19 12 2054 2062 (Pubitemid 41741597)
186. Entz-Werle N., Suciu S., van der Werff ten Bosch J., Vilmer E., Bertrand Y., Benoit Y., Margueritte G., Plouvier E., Boutard P., Vandecruys E., Ferster A., Lutz P., Uyttebroeck A., Hoyoux C., Thyss A., Rialland X., Norton L., Pages M. P., Philippe N., Otten J., Behar C., Robert A., Philippet P., Maes P., Plantaz D., Falkenrodt A., Fenneteau O., Lagrange M., Malet A. M., Manel A. M., Homolle E., Dastugue N., Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report Leukemia 2005 19 12 2072 2081 (Pubitemid 41741599)
187. Kuwatsuka Y., Miyamura K., Suzuki R., Kasai M., Maruta A., Ogawa H., Tanosaki R., Takahashi S., Koda K., Yago K., Atsuta Y., Yoshida T., Sakamaki H., Kodera Y., Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: T(8;21) and inv(16) represent different clinical outcomes Blood 2009 113 9 2096 2103
188. Gorin N.-C., Labopin M., Frassoni F., Milpied N., Attal M., Blaise D., Meloni G., Iori A. P., Michallet M., Willemze R., Deconninck E., Harousseau J.-L., Polge E., Rocha V., Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation Journal of Clinical Oncology 2008 26 19 3183 3188
189. Schlenk R. F., Pasquini M. C., Prez W. S., Zhang M. J., Krauter J., Antin J. H., Bashey A., Bolwell B. J., Bchner T., Cahn J. Y., Cairo M. S., Copelan E. A., Cutler C. S., Dhner H., Gale R. P., Ilhan O., Lazarus H. M., Liesveld J. L., Litzow M. R., Marks D. I., Maziarz R. T., McCarthy P. L., Nimer S. D., Sierra J., Tallman M. S., Weisdorf D. J., Horowitz M. M., Ganser A., HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR Biology of Blood and Marrow Transplantation 2008 14 2 187 196
190. Shin H. J., Kim H. J., Sohn S. K., Min Y. H., Won J. H., Kim I., Yoon H. J., Lee J. H., Jo D. Y., Joo Y. D., Jung C. W., Lee K. H., Chung J. S., Ahn J. S., Kim S. J., Lee JE. H., Choi S. J., Lee J. H., Bae S. H., Hong D. S., Zang D. Y., Kim S. H., Lee J. L., Bang S. M., Re-analysis of the outcomes of post-remission therapy for acute myeloid leukemia with core binding factor according to years of patient enrollment Japanese journal of clinical oncology 2010 40 6 556 566
191. Foran J. M., New prognostic markers in acute myeloid leukemia: perspective from the clinic Hematology American Society of Hematology Education Program 2010 2010 1 47 55
192. Bruserud., Stapnes C., Ersvr E., Gjertsen B. T., Ryningen A., Histone deacetylase inhibitors in cancer treatment: a review of the clinical toxicity and the modulation of gene expression in cancer cells Current Pharmaceutical Biotechnology 2007 8 6 388 400 (Pubitemid 350268198)
193. Ryningen A., Stapnes C., Paulsen K., Lassalle P., Gjertsen B. T., Bruserud., In vivo biological effects of ATRA in the treatment of AML Expert Opinion on Investigational Drugs 2008 17 11 1623 1633
194. Chen Z., Wang Y., Wang W., Gong J., Xue Y., All-trans retinoic acid as a single agent induces complete remission in a patient with acute leukemia of M subtype Chinese Medical Journal 2002 115 1 58 61 (Pubitemid 34130437)
195. Abreu E Lima R. S., Rozera Baruffi M., Gouveia De Lima A. S., De Oliveira F. M., De Figueiredo-Pontes L. L., Gonzaga Tone L., Rogatto S. R., Passetto Falco R., Ferrari Chauffaille M. D. L. L., Rego E. M., The co-expression of PML/RAR and AML1/ETO fusion genes is associated with ATRA resistance British Journal of Haematology 2005 128 3 407 409 (Pubitemid 40216167)
196. Kusec R., Laczika K., Knbl P., Friedl J., Greinix H., Kahls P., Linkesch W., Schwarzinger I., Mitterbauer G., Purtscher B., Haas O. A., Lechner K., Jaeger U., AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation Leukemia 1994 8 5 735 739 (Pubitemid 24161076)
197. Miyamoto T., Nagafuji K., Akashi K., Harada M., Kyo T., Akashi T., Takenaka K., Mizuno S. I., Gondo H., Okamura T., Dohy H., Niho Y., Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia Blood 1996 87 11 4789 4796 (Pubitemid 26162380)
198. Nucifora G., Larson R. A., Rowley J. D., Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission Blood 1993 82 3 712 715 (Pubitemid 23221647)
199. Saunders M. J., Tobal K., Liu Yin J. A., Detection of t(8;21) by reverse transcriptase polymerase chain reaction in patients in remission of acute myeloid leukaemia type M2 after chemotherapy or bone marrow transplantation Leukemia Research 1994 18 12 891 895
200. Jurlander J., Caligiuri M. A., Ruutu T., Baer M. R., Strout M. P., Oberkircher A. R., Hoffmann L., Ball E. D., Frei-Lahr D. A., Christiansen N. P., Block A. W., Knuutila S., Herzig G. P., Bloomfield C. D., Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia Blood 1996 88 6 2183 2191 (Pubitemid 26307921)
201. Schnittger S., Weisser M., Schoch C., Hiddemann W., Haferlach T., Kern W., New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFB-MYH11 acute myeloid leukemia based on quantification of fusion transcripts Blood 2003 102 8 2746 2755 (Pubitemid 37248843)
202. Leroy H., de Botton S., Gradel-Duflos N., Darre S., Leleu X., Roumier C., Morschhauser F., Lai J. L., Bauters F., Fenaux P., Preudhomme C., Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21) Leukemia 2005 19 3 367 372 (Pubitemid 40403312)
203. Ommen H. B., Schnittger S., Jovanovic J. V., Ommen I. B., Hasle H., stergaard M., Grimwade D., Hokland P., Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias Blood 2010 115 2 198 205
204. Al-Mawali A., Gillis D., Lewis I., The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia American Journal of Clinical Pathology 2009 131 1 16 26
205. Perea G., Lasa A., Aventn A., Domingo A., Villamor N., Paz Queipo de Llano M., Llorente A., Junc J., Palacios C., Fernndez C., Gallart M., Font L., Tormo M., Florensa L., Bargay J., Mart J. M., Vivancos P., Torres P., Berlanga J. J., Badell I., Brunet S., Sierra J., Nomdedu J. F., Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)] Leukemia 2006 20 1 87 94
206. Cox M. C., Panetta P., Venditti A., Del Poeta G., Franchi A., Buccisano F., Tamburini A., Maurillo L., Amadori S., Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients Hematology Journal 2003 4 4 263 270 (Pubitemid 36987222)
207. Bacher U., Kern W., Schoch C., Schnittger S., Hiddemann W., Haferlach T., Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia Cancer 2006 106 4 839 847 (Pubitemid 43238451)
208. Vance G. H., Kim H., Hicks G. A., Cherry A. M., Higgins R., Hulshizer R. L., Tallman M. S., Fernandez H. F., Dewald G. W., Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900) Leukemia Research 2007 31 5 605 609 (Pubitemid 46559998)
209. Grimwade D., Jovanovic J. V., Hills R. K., Nugent E. A., Patel Y., Flora R., Diverio D., Jones K., Aslett H., Batson E., Rennie K., Angell R., Clark R. E., Solomon E., Lo-Coco F., Wheatley K., Burnett A. K., Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy Journal of Clinical Oncology 2009 27 22 3650 3658
210. Esteve J., Escoda L., Martn G., Rubio V., Daz-Mediavilla J., Gonzlez M., Rivas C., lvarez C., San Miguel J. D. G., Brunet S., Toms J. F., Tormo M., Sayas M. J., Godoy P. S., Colomer D., Bolufer P., Sanz M. A., Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention Leukemia 2007 21 3 446 452
211. Morschhauser F., Cayuela J. M., Martini S., Baruchel A., Rousselot P., Soci G., Berthou P., Jouet J. P., Straetmans N., Sigaux F., Fenaux P., Preudhomme C., Evaluation of minimal residual disease using reverse- transcription polymerase chain reaction in t(8;21) acute myeloid leukemia: a multicenter study of 51 patients Journal of Clinical Oncology 2000 18 4 788 794 (Pubitemid 30106609)